Open an account

Clearone

CLRO · NASDAQ

$1.89+$0.17 (+9.88%)TodayMarket closed ·
Prev close $1.72

About CLRO

ClearOne, Inc. engages in the design, development, and marketing of professional audio conferencing, microphone, and video collaboration solutions. The company is headquartered in Salt Lake City, Utah. The firm designs, develops and sells conferencing, collaboration, and AV networking solutions for voice and visual communications. Its product categories include audio-conferencing, including installed DSP-based professional audio conferencing and USB-based speakerphones; professional microphones consisting of patented beamforming microphone arrays, ceiling microphones and wireless microphones, and video, including video collaboration and AV networking products. Its audio-conferencing products feature its proprietary HDConference, Distributed Echo Cancellation and noise cancellation technologies to enhance communication during a conference call by eliminating echo and background noise. Its professional conferencing products include the CONVERGE Pro 2 and CONVERGE Pro 2 SR product lines. Its premium conferencing offering consists of the CONVERGE Huddle product line.

Employees
80
Headquarters
Salt Lake City, Utah
Listed
Mar 3, 1989
Sector
Information Technology
Industry
Communications Equipment
Website
clearone.com

CLRO key statistics

Market cap
5.06M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
162.54K
Volume
187.44K
Open price
$1.88
High today
$2.03
Low today
$1.72
52 Week high
$16.50
52 Week low
$1.62

Clearone (CLRO) at a glance

As of Oct 20, 2026, Clearone (CLRO) shares are priced at $1.89, giving the company a market cap of 5.06M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.72 and $2.03. The current price is 9.8% above the day's low and 6.7% below its high.

Volume so far is 187.44K shares, in line with the average of 162.54K shares a day.

Over the past year Clearone has ranged from $1.62 to $16.50, and now sits 2% of the way up that range.

Clearone met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY18 it reported -$3.30 per share against an estimate of -$3.83.

CLRO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 20.4% on average.

  1. Q3 FY16: reported $3.30 per share against an estimate of $3.29
  2. Q4 FY16: reported -$0.30 per share against an estimate of $3.21
  3. Q1 FY17: reported $0.30 per share against an estimate of $2.68
  4. Q2 FY17: reported -$0.15 per share against an estimate of $1.22
  5. Q3 FY17: reported $1.35 per share against an estimate of $0.918
  6. Q4 FY17: reported -$4.05 per share against an estimate of $0.8415
  7. Q1 FY18: reported -$2.70 per share against an estimate of $1.07
  8. Q2 FY18: reported -$3.30 per share against an estimate of -$3.83

CLRO news

  • Avi Kapoor

    Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

  • 12 Information Technology Stocks Moving In Thursday's Intraday Session

  • 12 Information Technology Stocks Moving In Tuesday's Intraday Session

  • 12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

  • 12 Information Technology Stocks Moving In Monday's After-Market Session

  • 12 Information Technology Stocks Moving In Thursday's Intraday Session

  • Press releaseGlobe Newswire

    Why Investors Are Watching These Healthcare Movers

  • Avi Kapoor

    Nasdaq Down 50 Points; US Foods Posts Upbeat Earnings

Similar companies

Companies in the same industry as Clearone

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.